Datasheet

生物学的記述

Specificity	CDK12 Antibody [N24C20] detects endogenous levels of total CDK12 protein.
Background	CDK12 is a transcription‑associated cyclin‑dependent kinase that forms an active complex with cyclin K and functions as a carboxyl‑terminal domain (CTD) kinase for RNA polymerase II, thereby acting as a global regulator of transcription elongation and RNA processing with particular impact on long genes involved in DNA damage responses and genome maintenance. The kinase contains a canonical CDK catalytic core with an activation loop and a large C‑terminal extension that contributes to CTD binding and substrate selectivity, and the CDK12–cyclin K complex phosphorylates Ser2 and Ser5 residues within heptad repeats of the RNAPII CTD, enhancing processive elongation and productive transcription across gene bodies. CDK12 activity stimulates RNAPII elongation on a broad set of protein‑coding genes and also influences transcription termination, co‑transcriptional splicing, and RNA turnover, in part through direct phosphorylation of RNA‑processing factors that associate with the elongating polymerase. CDK12 has a strong functional bias toward long, complex genes encoding key DNA damage response and homologous recombination proteins such as BRCA1, ATR, FANCI, and other HR factors; inhibition or loss of CDK12 causes gene length‑dependent elongation defects, premature cleavage and polyadenylation within introns, and marked down‑regulation of these DDR transcripts, leading to reduced DNA repair capacity and genomic instability. This selectivity arises from the combination of CTD phosphorylation defects and altered regulation of pre‑mRNA processing at intronic polyadenylation sites, making long DDR genes particularly sensitive to reduced CDK12‑dependent elongation and processing. CDK12 also regulates expression of core DNA replication genes and other cell‑cycle regulators by controlling RNAPII processivity over these loci, thereby contributing to proper G1/S progression and coordination between replication and repair. In cancer, recurrent CDK12 loss‑of‑function mutations occur in high‑grade serous ovarian carcinoma, prostate cancer, and other tumor types and associate with tandem duplications, focal genomic rearrangements, and a distinct genomic instability signature that reflects defective transcription of homologous recombination genes rather than direct catalytic lesions in replication or repair enzymes.

Specificity

CDK12 Antibody [N24C20] detects endogenous levels of total CDK12 protein.

Background

CDK12 is a transcription‑associated cyclin‑dependent kinase that forms an active complex with cyclin K and functions as a carboxyl‑terminal domain (CTD) kinase for RNA polymerase II, thereby acting as a global regulator of transcription elongation and RNA processing with particular impact on long genes involved in DNA damage responses and genome maintenance. The kinase contains a canonical CDK catalytic core with an activation loop and a large C‑terminal extension that contributes to CTD binding and substrate selectivity, and the CDK12–cyclin K complex phosphorylates Ser2 and Ser5 residues within heptad repeats of the RNAPII CTD, enhancing processive elongation and productive transcription across gene bodies. CDK12 activity stimulates RNAPII elongation on a broad set of protein‑coding genes and also influences transcription termination, co‑transcriptional splicing, and RNA turnover, in part through direct phosphorylation of RNA‑processing factors that associate with the elongating polymerase. CDK12 has a strong functional bias toward long, complex genes encoding key DNA damage response and homologous recombination proteins such as BRCA1, ATR, FANCI, and other HR factors; inhibition or loss of CDK12 causes gene length‑dependent elongation defects, premature cleavage and polyadenylation within introns, and marked down‑regulation of these DDR transcripts, leading to reduced DNA repair capacity and genomic instability. This selectivity arises from the combination of CTD phosphorylation defects and altered regulation of pre‑mRNA processing at intronic polyadenylation sites, making long DDR genes particularly sensitive to reduced CDK12‑dependent elongation and processing. CDK12 also regulates expression of core DNA replication genes and other cell‑cycle regulators by controlling RNAPII processivity over these loci, thereby contributing to proper G1/S progression and coordination between replication and repair. In cancer, recurrent CDK12 loss‑of‑function mutations occur in high‑grade serous ovarian carcinoma, prostate cancer, and other tumor types and associate with tandem duplications, focal genomic rearrangements, and a distinct genomic instability signature that reflects defective transcription of homologous recombination genes rather than direct catalytic lesions in replication or repair enzymes.

使用情報

Application

WB, IP, IHC

Dilution

WB	IP	IHC
1:1000	1:30	1:500

Reactivity

Human, Mouse, Rat

Source

Rabbit Monoclonal Antibody

MW

164 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

プロトコール

References

https://pubmed.ncbi.nlm.nih.gov/30988284/
https://pubmed.ncbi.nlm.nih.gov/32805052/

CDK12 Antibody [N24C20]

生物学的記述

使用情報

References

Application Data